Clinical Trial

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

Study acronym: ENTRANCE
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).
Protocol Amendment History 3 changes
critical Primary endpoint(s) modified 2026-07-08
notable Enrollment increased: 107 -> 130 participants 2026-07-08
minor Trial arms changed: 3 -> 4 2026-07-08
Trial Details
NCT Number NCT07053384
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 130 participants
Start Date 2025-07-10
Primary Completion 2027-01-22 (estimated)
Study Completion 2028-09-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-07